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Introduction
The solid organ transplantation belongs to the great success stories of the XXth. century. Life expectancy and quality of life are affected by the side effects rather than the transplantation itself. Upper gastrointestinal (GI) symptoms are frequent in organ transplant recipients. Peptic ulcer and related pathologies such as gastritis and duodenitis are known to occur with increased frequency (20-60%) and severity in renal transplant recipients. The frequency of severe complications is about 10% and 10% of those might prove fatal. Ulcer disease is one of the most important GI disorders. Peptic ulcer was a frequent cause of mortality until a few years ago, accounting for about 4% of deaths after transplantation. Historically ulcer healing was required for performing kidney transplant. More recently, however, the prognosis has improved and mortality or graft losses because of peptic ulcer have become exceptional.
Today, many transplant groups use prophylactic acid supressive therapy (AST) after operation. Despite of that there is no data of frequency of ulcer disease of endoscopically examined kidney transplant recipients. GI symptoms at the immediate perioperative period may be caused by uraemia, stress, and the operation itself. Later on, the patients have to take numerous pills every day. The role of corticosteroids is still controversial but it is likely that the high doses of corticosteroids used for treating rejection may have an ulcerogenic effect. Nausea, vomiting, dyspepsia, and anorexia are particularly frequent in patients given mycophenolat-mofetil (MMF). Other causes of gastroduodenal disorders include Helicobacter pylori, cytomegalovirus (CMV) and mycotic infections.
Over the last 25 years, there has been considerable interest in the role of H. pylori in the pathogenesis of gastritis and peptic ulceration in the general population. However, results of earlier studies concerning dialysis and/or transplant patients are conflicting. Statements about H. pylori infection frequency in these populations vary from 'less than normal population' up to 'higher as in the normal', but very few studies checked a considerable number of patients.
Published data of sero-positivity vary from 31% to 92%. In the general population only 15% of H. pylori infected persons develop peptic ulcer disease, suggesting that specific factors are required for ulceration to occur. Genetic variability influences susceptibility to several diseases. HLA-class II genes (located at the 6th chromosome) have been repeatedly investigated as candidate genes for predisposition to H. pylori infection. So far, the reported results are conflicting on that count too. Results from other ethnically different (mainly Chinese and Japanese) populations are variable.
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A debate is still ongoing on the clinical significance of the presence of the H.pylori in the stomach after transplantation.
Although upper GI endoscopy is part of the everyday medical practice, only few studies have been done on the endoscopic findings of renal patients and include only small numbers.
Treatment of these complains are based mainly on local habits and theories. The gastrointestinal tract accounts for a large component of non-allograft-related complications seen after all types of solid organ transplantation. Serious GI complications are responsible for 1-4% of mortality after kidney transplant. Majority of the complications requiring operation occurs urgently with a mortality rate of 30%. 5-year patient survival rate in patients with a first year complication is 68% compared to 88% in patients with a later or no GI complication. GI complications might require dose reduction or the discontinuation of some of the immunosuppressive medications, affecting graft survival. 
Endoscopy
Socio-economic study
In 2004, a socio-economic study was performed using a questionnaire containing 25 questions about living conditions.
Immunosuppression
The immunosuppressive (IS) medication used at the time of endoscopy was collected and analysed. The most frequently used (75.1%) immunosuppressive combinations were cyclosporine-mycophenolat mofetil-steroid (CSA-MMF-ST) triple (51.2%), cyclosporinesteroid (CSA-ST) double (27.3%) and tacrolimus-mycophenolat-steroid (TAC-MMF-ST) triple (21.5%) therapy. All other combinations occurred in less than 5% in that material, and these were excluded from immunosuppressive-analysis.
Ulcer prophylaxis
Data of acid suppressive therapy (AST) before endoscopy was collected and analysed. Nearly all (97.8%) patients got AST. Out of them 56.2% received histamine receptor antagonist (H 2 RA), 43.8% proton pump inhibitor (PPI), without age or gender difference. There was a variable usage of PPI-s and H 2
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receptor antagonists; however, the general trend of the rate did not change during the study period. There was no difference between the IS groups according to AST, p=0.26.
Qualitative data were analysed by Fisher's exact test or with "2 by k" chi-square test with a two-sided probability value. Continuous variables were presented mean or median and compared using the Mann-Whitney U or Kruskal-Wallis test. The influence of risk factors was quantified using odds ratio (OR). P values of below 0.05 were considered significant. 
Serology and HLA
Helicobacter pylori and sero-epidemiology
Serologic testing for H. pylori was uncertain in 17 cases (2.34%) and thus, these cases were excluded from analysis. Of the remaining 709 patients, 350 (49.37%) were H. pylori seropositive and 359 (50.63%) were seronegative, without differences according to gender. In the first year (2001) of our study, sero-positivity rate was at 62.5%, whereas for 2006 it gradually decreased to 35%. Mean age of positive patients was 48.9 years (9-74, SD: ±11.74), whereas the mean age of negative patients was 41.0 years (3-71, SD: ±16.1); this difference was highly significant (p<0.0001). Taking into account only the adults (>18 years), mean ages of positive and negative patients were 49.5 and 44.6 years, respectively, p<0.001. H. pylori occurred mainly among elderly patients: only 13% were under 18 years and more than 60%
were over 60 years. There was no change in the mean age of patients during the study period. 
Socio-economic study
The presence of H.p. did not differ according to family size: it was 51% is small and 58% in larger families, p=0.74. Sero-prevalence was independent from qualification of both the parents (p=0.12) and the patients (p=0.74). Neither childhood's nor present place of residence (small village or town/capital) affected to rate of H.p. infection. There was no difference in 
HLA distribution
The association between the HLA and H. pylori serologic status was analyzed by comparing the carrier frequency (frequency of individuals positive for a particular allele) of seronegative and seropositive patients. No difference was found in class I (HLA-A, B, C) 
Endoscopy
We performed 56/year upper endoscopies in average for kidney transplant patients. The yearly fluctuation of it follows the numbers of transplantations.
Indication
The most frequent indications for endoscopy were pain (46.2%), dyspeptic complaints (23.2%), bleeding (18.4%) and anaemia (10.7%). There were some other non-specific or "ad hoc" indications like unknown fever, percutaneous endoscopic gastrostomy, jaundice, portal hypertension, food-block, recurrent pancreatitis.
Disorders
The most frequent indications are presented in Table 2 . Only 16.2% of the patients examined had absence of any endoscopic findings. Out of 92 ulcer patients 52 (56.5%) had gastric, 33 (35.8%) duodenal and 7 (7.6%) had both kinds of ulcer. In five cases, malignant tumour was suspected during the endoscopy with three of them histologically proven: one was MALT-lymphoma, the others were adenocarcinomas.
Histology
Histological examinations were completed in 484 patients. Histologic abnormalities, mainly inflammatory alterations, were proven in 84.6% of patients. Metaplasia was observed in 2.2%
(10 patients), tumour in 1.2% (6 pts.). Histology proved the presence of two carcinoid, three adenocarcinomas and one MALT-lymphoma.
Infections
Helicobacter pylori
Out of the histologically examined 481 patients, the presence of Helicobacter pylori was 
Cytomegalovirus
The presence of cytomegalovirus (CMV) in the GI mucosa was proven in 53.4% of the patients. There was no difference in the mean age (p=0. 
Mycosis
Mycotic infection, mainly oesophageal candidiasis, was seen in 11.2% of the patients. It was strongly associated with oesophageal ulceration (OU): 6 out of 61 patients with, and 16 out of 481 patients without mycosis had OU, p=0.028, OR=2.57, (1.19-4.85 CI:95%). Mycosis had no association with either duodenal or gastric ulceration, p=0.47.
Immunosuppressant's impact
In the main IS groups there were no differences in the incidence of negative findings (p=0.53), inflammation (p=0.15), ulcer (p=0.77), and oesophagitis (p=0.47) and the presence of H. pylori (p=0.44). However, there were differences in the incidence of erosive laesions and the presence of CMV (Table 3 .) 
Acid supressive therapy's impact
I compared the H 2 Table 4 RA and PPI groups according to the indications, observed diagnoses and infections. The only significant difference was in the presence of H.pylori; it was less frequent in the PPI group ( ). 
Renal function's impact
The renal function was described by the creatinine level. The vast majority of the patients had a good renal function, median creatinine reading was 137 µmol/l (60-700, SD+103.5). It had no impact on GI complains, endoscopic findings or infections. 
Timing of endoscopy
The time between transplantation and endoscopy varies from three days up to almost 19 years, median was 3.39y. However, 29% (157) of patients were examined in the first posttransplant year, and 58.5% (92) of them, which is 16.9% of all, in the first three months. Of those having pain median time was significantly shorter (p=0.00014). Ulcer was more commonly found in 1. In the whole investigated uraemic population sero-positivity for the Helicobacter pylori was 49.3%, owing to the cohort effect. It decreased gradually from 65% to 35% in investigation period. Analyzing the birth-year groups, I concluded that prevalence of infection decreases strongly with year of birth, and not with age itself, as H. pylori infection is typically acquired in early childhood.
2. Decreased infection rate of uraemic patients and the general population ran together.
We published our observations and opinion based on the largest database in the literature. These results suggest that eradication happens at the very early peri-operativ period, when prophylactic antibiotics and AST are given together. Due to the constant use of AST, sensitivity of RUT was proven very low. We gave it up, and do not recommend it in that particular group of patients. The presence of H. pylori did not result in significant postoperative gastric complications. This finding suggests that ulceration in transplant recipients is a multifactorial process that may involve the interaction of acid secretion, H. pylori, immunosuppressive agents and other medication. Presence of H.pylori and CMV were independent from each other.
9. The rate of observed endoscopic alterations did not differ in the H 2 10. I did not observe any impact of the renal function to GI complains.
RA and in the PPI group, indicating the equivalence of these two groups of AST in this setting. The only difference was in the presence of H. pylori, PPIs facilitated the eradication "by chance" more efficiently as it does in the general population.
14 11. The most important period for upper GI symptoms requiring endoscopy was the first year and particularly the first three months. Almost one third of the patients were investigated in the first year. In the first three months 29%, in the first year 26% of the endoscopic examinations revealed an ulcer disease. Out of 92 ulcers 29% developed in the first three months and 45.7% in the first posttransplant year.
Take Home Message: It seems worth to continue to scientific work on the relation between Helicobacter pylori and HLA-system. The importance of it to the everyday clinical practice is unpredictable.
Specific immunosuppressive drugs, opportunistic infections and other clinical circumstances that affect transplant patients are not seen frequently in the general practice of gastroenterology. Thus, the endoscopist at a transplant centre has to be able to recognize, identify, and treat the unique problems seen in a transplant population. While performing endoscopy obtaining biopsy samples is mandatory. Giving prophylactic acid secretion blockers, minimizing the number of pills a patient has to take a day and adopting a low threshold for endoscopy are among the most important measures that can be used to avoid GI complications after transplantation
